Sanofi Expands Oncology Portfolio with NK Cell Engager In-License from Innate Pharma
Sanofi (NASDAQ: SNY) has in-licensed a natural killer (NK) cell engager candidate for solid tumors...
Huadong Medicine Strikes Exclusive Promotion Deal with Impact Therapeutics for Senaparib in China
China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an exclusive market promotion service...
Konruns Pharmaceutical Gets NMPA Approval for KC1036 Clinical Study in Juventus sarcoma
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has received approval from the National Medical Products...
Staidson Pharmaceutical’s BDB-001 Earns Breakthrough Therapy Designation in China for AAV Treatment
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that its...
3SBio Subsidiary Gets Green Light for SSGJ-608 Ankylosing Spondylitis Study
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has received...
Lynk Pharmaceuticals Initiates Phase III Clinical Trial for Rheumatoid Arthritis Drug in China
China-based Lynk Pharmaceuticals Co., Ltd has announced that the first patient has been dosed in...
Tower Cold Chain Expands into China with Partnership with Tower & Winner Solutions
Tower Cold Chain, a UK-based specialist in pharmaceutical container solutions, has announced a partnership with...
Biocytogen Pharmaceuticals Inks Antibody Deal with Neurocrine Biosciences
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) has announced an antibody assessment and option...
China Grand Pharmaceuticals Secures Distribution of Sirtex’s SIR-Spheres for Liver Cancer
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) announced that its subsidiaries, Beijing...
Organon In-Licenses Eli Lilly’s Emgality and Rayvow for European Migraine Market
Organon (NYSE: OGN), a specialist in women’s health, has in-licensed migraine treatments Emgality (galcanezumab) and...
European Commission Expands Keytruda Indications for Advanced Cancer Treatments
The European Commission (EC) has granted Merck, Sharp & Dohme (MSD; NYSE: MRK) additional indications...
HuidaGene Secures Rare Pediatric Disease Designation for CRISPR Therapy HG302 Targeting DMD
HuidaGene Therapeutics, based in China, has announced that it has received Rare Pediatric Disease Designation...
Blue Sail Medical Partners with Weifang Government on Healthcare Initiative
China’s Blue Sail Medical Co., Ltd. (SHE: 002382) has announced strategic cooperation agreements with the...
HighField Biopharmaceutical Doses First Patient in HFK1 Clinical Trial Targeting Solid Tumors
Hangzhou-based HighField Biopharmaceutical, a leader in immuno-oncology focused on innovative lipid-based therapies, has announced the...
Kangtai Biological Partners with Bahrain Pharma Firm on Strategic Vaccine Production Agreement
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a prominent player in China’s biotechnology sector,...
EMA’s CHMP Gives Green Light to Sanofi’s Fexinidazole for Acute Sleeping Sickness Treatment
Last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
BGI Genomics Receives NMPA Approval for Innovative Colorectal Cancer Detection Kit
BGI Genomics Co., Ltd. (SHE: 300676), a leading genomics firm based in China, has announced...
InventisBio’s KRAS G12C Inhibitor D-1553 Advances Toward Priority Review in China
According to the China Center for Drug Evaluation (CDE), Shanghai-based InventisBio Co., Ltd. (SHA: 688382)...
GSK’s CCO Calls China a Hotbed for Innovative Molecules and Licensing Deals
In an interview with the Financial Times, Luke Miels, Chief Commercial Officer of UK-based GlaxoSmithKline...
Biocytogen and Ona Therapeutics Forge Antibody Evaluation and Licensing Agreement
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), based in China, has entered into an antibody...